Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenet Healthcare (THC) and Pacific Biosciences (PACB)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tenet Healthcare (THC – Research Report) and Pacific Biosciences (PACB – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tenet Healthcare (THC)
Wells Fargo analyst Stephen Baxter maintained a Buy rating on Tenet Healthcare on February 13 and set a price target of $265.00. The company’s shares closed last Friday at $231.10.
According to TipRanks.com, Baxter is a 1-star analyst with an average return of
Currently, the analyst consensus on Tenet Healthcare is a Strong Buy with an average price target of $259.50, a 12.3% upside from current levels. In a report issued on February 13, TipRanks – xAI also upgraded the stock to Buy with a $255.00 price target.
See the top stocks recommended by analysts >>
Pacific Biosciences (PACB)
Guggenheim analyst Subbu Nambi maintained a Hold rating on Pacific Biosciences on February 12. The company’s shares closed last Friday at $1.71.
According to TipRanks.com, Nambi is a 5-star analyst with an average return of
Pacific Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $2.50, which is a 32.3% upside from current levels. In a report issued on February 5, Piper Sandler also maintained a Hold rating on the stock with a $2.00 price target.
